Angiomyxoma is a myxoid tumor involving the blood vessels.
It can affect the vulva and other parts of the pelvis. The characteristic feature of this tumor is its frequent local recurrence and it is currently regarded as a non-metastasizing benign tumor.
Genetics HMGA2 rearrangement by translocation t(12;21)(q15;q21.1) by translocation t(11;12)(q23;q15) by translocation t(8;12)(p12;q15) t(5;8)(p15;q22)
Pathology Microscopy Vascular appearance of tumor Hypocellular mesenchymal lesion Spindled and stellate cells with an ill-defined cytoplasm Cells loosely scattered in a myxoid stroma No evidence of nuclear atypia and mitosis Numerous, thin-to-thick wall vessels of different sizes Myxoid, hypocellular background Bland cytological appearance of spindle cells
Microscopical views
Immunochemistry Immunohistochemical studies show strong staining for desmin, estrogen receptors, and progesterone receptors. Staining for actin, CD34 and smooth muscle actin are intermediate. Staining for S-100 protein is negative.
Diagnosis Differential diagnosis Myxoid tumors Angiomyofibroblastoma
Prognosis Although it is a benign tumour and does not invade neighbouring tissues, it has a tendency to recur after surgical excision so it is termed "aggressive". Recurrence can occur as early as six months from initial resection. Patients frequently present at tertiary medical centers with a history of labial mass (sometimes misdiagnosed as Gartner's cyst), with multiple surgical excisions from several surgeons. There is no standard medical therapy; agents reported to be effective in case reports include systemic hormonal therapy with SERMs such as tamoxifen or LHRH agonists (leuprolide), and cytotoxic ("traditional") chemotherapy, as well as radiation therapy especially for recurrent disease.
History Aggressive angiomyxoma was originally described in 1983, but the term angiomyxoma dates back to at least 1952.
See also Myxoma Cutaneous myxoma (Superficial angiomyxoma)
References
External links